ABSTRACT
Peptidyl arginine deiminase 4 (PADI4), an enzyme that converts arginine residues to citrulline residues in the presence of calcium ions, affects the biochemical activities of proteins. The biological function of PADI4 as well as its mechanism in nasopharyngeal carcinoma (NPC) necessitates further investigation. PADI4 expression in NPC tissues and cells was detected using Western blot. qRT-PCR was used to determine the expression of miR-335-5p and PADI4 mRNA in NPC tissues and cells. BrdU assay and CCK-8 assay were employed to detect cell proliferation. Cell migration and invasion were evaluated using Transwell assay. NPC cells were exposed to different doses of radiation in vitro, and then colony formation assays were used to detect colony survival. The target relationship between miR-335-5p and PADI4 was verified using Western blot, qRT-PCR, and dual-luciferase reporter gene assays. Compared with normal mucosal epithelial tissues and cell lines, the expression level of PADI4 in NPC tissues and cells was significantly up-regulated. PADI4 overexpression promoted the proliferation, migration, and invasion of NPC cells. Under radiation, NPC cell survival was significantly promoted by the up-regulation of PADI4. Conversely, knock-down of PADI4 suppressed the above-mentioned malignant phenotypes. MiR-335-5p could bind with the 3' UTR of PADI4 mRNA, and suppressed the expression of PADI4. PADI4 down-regulated the expression of p21 and activated the mTOR signaling pathway. PADI4, which is negatively regulated by miR-335-5p, promotes the proliferation, migration, invasion and radioresistance of NPC cells by regulating the p21 and mTOR signaling pathways.
Subject(s)
MicroRNAs/supply & distribution , Nasopharyngeal Carcinoma , Nasopharyngeal Neoplasms , Cell Line, Tumor , Cell Movement , Cell Proliferation , Gene Expression Regulation, Neoplastic , Humans , Nasopharyngeal Carcinoma/genetics , Nasopharyngeal Neoplasms/genetics , Nasopharyngeal Neoplasms/radiotherapy , Protein-Arginine Deiminase Type 4 , Radiation Tolerance/geneticsABSTRACT
In this study, we optimized a restriction-ligation-free (RLF) method to save time and cost of constructing multiple plasmids with the same gene insert, and examined the efficacy of RLF on high-throughput multi-plasmid cloning. This method utilizes the precise DNA repair and recombination systems within Escherichia coli, which allows to bypass the in vitro restriction and ligation enzyme reactions commonly included in routine cloning procedures. A homologous arm is linked to the 5'-end of the forward primer used to amplify both the target gene and vector. A different homologous arm is linked to the 5'-end of the reverse primer. Therefore, genes can be cloned into the vectors by homologous recombination after co-transformation of the amplified target gene and the linearized vector, which bear the same homologous arm on either end. More than twenty-four different plasmids were generated by this method, which uses two simple polymerase chain reaction steps. This method is highly efficient in cloning any gene of interest into any vector at any site without sequence constraints, as no restriction and ligation reactions are required.
Subject(s)
Cloning, Molecular/methods , Cloning, Molecular/drug effects , Genetic Vectors/genetics , Plasmids/genetics , Polymerase Chain ReactionABSTRACT
Receptor-interacting protein (RIP140) is a transcription co-regulator highly expressed in macrophages to regulate inflammatory and metabolic processes. However, its implication in neurological, cognitive and emotional conditions, and the cellular systems relevant to its biological activity within the central nervous system are currently less clear. A transgenic mouse line with macrophage-specific knockdown of RIP140 was generated (MΦRIPKD mice) and brain-region specific RIP140 knockdown efficiency evaluated. Mice were subjected to a battery of tests, designed to evaluate multiple behavioral domains at naïve or following site-specific RIP140 re-expression. Gene expression analysis assessed TNF-α, IL-1ß, TGF-1ß, IL1-RA and neuropeptide Y (NPY) expression, and in vitro studies examined the effects of macrophage's RIP140 on astrocytes' NPY production. We found that RIP140 expression was dramatically reduced in macrophages within the ventromedial hypothalamus (VMH) and the cingulate cortex of MΦRIPKD mice. These animals exhibited increased anxiety- and depressive-like behaviors. VMH-targeted RIP140 re-expression in MΦRIPKD mice reversed its depressive- but not its anxiety-like phenotype. Analysis of specific neurochemical changes revealed reduced astrocytic-NPY expression within the hypothalamus of MΦRIPKD mice, and in vitro analysis confirmed that conditioned medium of RIP140-silnenced macrophage culture could no longer stimulate NPY production from astrocytes. The current study revealed an emotional regulatory function of macrophage-derived RIP140 in the VMH, and secondary dysregulation of NPY within hypothalamic astrocyte population, which might be associated with the observed behavioral phenotype of MΦRIPKD mice. This study highlights RIP140 as a novel target for the development of potential therapeutic and intervention strategies for emotional regulation disorders.
Subject(s)
Anxiety/metabolism , Depression/metabolism , Macrophages/metabolism , Nuclear Receptor Co-Repressor 1/metabolism , Ventromedial Hypothalamic Nucleus/metabolism , Animals , Astrocytes/metabolism , Brain/metabolism , Cytokines/metabolism , Emotions/physiology , Gene Knockdown Techniques , Male , Mice , Neuropeptide Y/metabolism , Nuclear Receptor Co-Repressor 1/genetics , Phenotype , RNA, Messenger/metabolismABSTRACT
Microglial activation worsens neuronal loss and contributes to progressive neurological diseases like Parkinson's disease (PD). This inflammatory progression is countered by dynorphin (Dyn), the endogenous ligand of the kappa-opioid receptor (KOR). We show that microglial ß-arrestin mediates the ability of Dyn/KOR to limit endotoxin-elicited production of pro-inflammatory effectors and cytokines, subsequently protecting neurons from inflammation-induced neurotoxicity. Agonist-activated KOR enhances the interaction of ß-arrestin2 with transforming growth factor-beta-activated kinase 1 (TAK1)-binding protein 1 (TAB1), disrupting TAK1-TAB1 mediated pro-inflammatory gene expression. We reveal a new physiological role for ß-arrestin in neuroprotection via receptor internalization-triggered blockade of signal effectors of microglial inflammatory neurotoxicity. This result offers novel drug targets in the convergent KOR/ß-arrestin2 and inflammatory pathways for treating microglial inflammatory neuropathologies like PD.
Subject(s)
Arrestins/metabolism , Microglia/metabolism , Neurons/metabolism , Opioid Peptides/metabolism , Parkinson Disease/metabolism , Adaptor Proteins, Signal Transducing/metabolism , Animals , Cell Death/physiology , Cytokines/biosynthesis , Dynorphins/metabolism , Female , Inflammation/metabolism , Inflammation/pathology , MAP Kinase Kinase Kinases/metabolism , Male , Mice , Mice, Inbred C57BL , Microglia/pathology , Neurons/pathology , Parkinson Disease/pathology , Pregnancy , Receptors, Opioid, kappa/agonists , Receptors, Opioid, kappa/metabolism , beta-ArrestinsABSTRACT
Mobilization and translation of mRNAs, two important events believed to involve stress granules (SGs), in neurons are important for their survival and activities. However, the formation and disassembly of SGs in neurons remains unclear. By using an arsenite-induced neuronal stress model of rat primary spinal cord neuron cultures, we demonstrate the formation of SGs that contain common SG components and RNAs in both stressed neuronal cell bodies and their neurites. By employing small interfering RNA (siRNA) knockdown, we discovered that dynein motor subunit localizes in SG, and is important for SG assembly in neurons. Under stress, dynein motor subunit also facilitates translational repression and enhances the formation and integrity of SG in neurons. By blocking the energy source of dynein motor, both the formation and disassembly of SG are attenuated. These findings demonstrate, for the first time, that dynein motor complex plays a critical role in the dynamics of neuronal SGs, as well as translation of certain mRNAs.
Subject(s)
Carrier Proteins/metabolism , Cytoplasmic Granules/metabolism , Drosophila Proteins/metabolism , Motor Neurons/cytology , Nonlinear Dynamics , Adenine/analogs & derivatives , Adenine/pharmacology , Adenylyl Imidodiphosphate/pharmacology , Animals , Animals, Newborn , Antigens, Surface/metabolism , Arsenites/pharmacology , Carrier Proteins/genetics , Cell Count/methods , Cells, Cultured , Cysteine/metabolism , Cytoplasmic Granules/drug effects , Dose-Response Relationship, Drug , Drosophila Proteins/genetics , Dyneins , ELAV Proteins , ELAV-Like Protein 1 , Endopeptidase K/pharmacology , Enzyme Inhibitors/pharmacology , Indoles , Methionine/metabolism , Motor Neurons/drug effects , Motor Neurons/physiology , Protein Subunits/metabolism , Protein Transport/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/pharmacology , RNA-Binding Proteins/metabolism , Rats , Spinal Cord , Stress, Physiological/drug effects , Stress, Physiological/physiology , Sulfur Isotopes/metabolism , Teratogens/pharmacology , Time FactorsABSTRACT
The gene of mouse kappa opioid receptor (KOR) utilizes two promoters, P1 and P2. P1 is active in various brain areas and constitutively in P19 mouse embryonal carcinoma cells. P2 is active in limited brain stem areas of adult animals and only in late differentiated cells of P19 induced for neuronal differentiation in the presence of nerve growth factor (NGF). NGF response of P2 was found to be mediated by a specific binding site for transcription factor activation protein 2 (AP2) located in P2. Electrophoretic gel shift assay showed specific binding of this AP2 site by AP2beta, but not AP2alpha. Knockdown of endogenous AP2beta with siRNA abolished the stimulating effect of NGF on the expression of transcripts driven by P2. Binding of endogenous AP2beta on the endogenous KOR P2 chromatin region was also confirmed by chromatin immunoprecipitation. The effect of NGF was inhibited by LY2942002 (phosphatidylinositol 3-kinase, PI3K inhibitor), suggesting that PI3K was involved in signaling pathway mediating the effect of NGF stimulation on KOR P2. The chromatin of P2 in P19 was found to be specifically modified following NGF stimulation, which included demethylation at Lys9 and dimethylation at Lys4 of histone H3 and was consistent with the increased recruitment of RNA polymerase II to this promoter. This study presents the first evidence for epigenetic changes occurred on a specific KOR promoter triggered by NGF in cells undergoing neuronal differentiation. This epigenetic change is mediated by recruited AP2beta to this promoter and involves the PI3K system.
Subject(s)
Cell Differentiation/physiology , Epigenesis, Genetic/physiology , Neurons/metabolism , Receptors, Opioid, kappa/genetics , Animals , Cell Differentiation/drug effects , Chromatin Immunoprecipitation/methods , Dose-Response Relationship, Drug , Drug Interactions , Electrophoresis, Polyacrylamide Gel , Electrophoretic Mobility Shift Assay/methods , Enzyme Inhibitors/pharmacology , Epigenesis, Genetic/drug effects , Luciferases/metabolism , Mice , Models, Biological , Nerve Growth Factor/pharmacology , Neurons/drug effects , PC12 Cells/drug effects , Promoter Regions, Genetic/drug effects , RNA, Small Interfering/metabolism , RNA, Small Interfering/pharmacology , Rats , Receptors, Opioid, kappa/metabolism , Transfection , Tretinoin/pharmacologyABSTRACT
Orphan nuclear receptor TR2 is a preadipocyte proliferator. Knockdown of TR2 in 3T3-L1 preadipocytes reduced their proliferation efficiency, whereas specific elevation of TR2 in these cells facilitated their proliferation. All-trans retinoic acid (RA) stimulates cellular proliferation in 3T3-L1 preadipocytes by activating TR2 through an IR0-type RA response element, which further activates c-Myc expression. In post-differentiated adipocytes, RA becomes a repressive signal for TR2 and rapidly down-regulates its expression. The biphasic effect of RA on TR2 expression in 3T3-L1 is mediated by differential RA-dependent coregulator recruitment to the receptor/Glucocorticoid Receptor-Interacting Protein 1 (GRIP1) complex that binds IR0 on the TR2 promoter. RA induces the recruitment of histone acetyl transferase-containing/GRIP1/p300/CBP-associated factor (PCAF) complex to the TR2 promoter in undifferentiated cells, whereas it triggers recruitment of histone deacetylase-containing/GRIP1/receptor-interacting protein 140 (RIP140) complex in differentiated cells. GRIP1 directly interacts with RIP140 through its carboxyl terminal AD2 domain. GRIP1 interacts with PCAF and RIP140 directly and differentially, functioning as a platform molecule to mediate differential RA-induced coregulator recruitment to TR2 promoter target. This results in a biphasic effect of RA on the expression of TR2 in undifferentiated and differentiated cells, which is required for RA-stimulated preadipocyte proliferation.
Subject(s)
Adipocytes/metabolism , Receptors, Thyroid Hormone/metabolism , Stem Cells/metabolism , Transcription Factors/metabolism , Tretinoin/pharmacology , 3T3-L1 Cells , Adaptor Proteins, Signal Transducing/chemistry , Adaptor Proteins, Signal Transducing/metabolism , Adipocytes/cytology , Adipocytes/drug effects , Animals , Binding Sites , Cell Cycle Proteins/metabolism , Cell Differentiation , Cell Proliferation/drug effects , Histone Acetyltransferases/metabolism , Mice , Nuclear Proteins/chemistry , Nuclear Proteins/metabolism , Nuclear Receptor Coactivator 2/chemistry , Nuclear Receptor Coactivator 2/metabolism , Nuclear Receptor Interacting Protein 1 , Nuclear Receptor Subfamily 2, Group C, Member 1 , Promoter Regions, Genetic , Protein Structure, Tertiary , Receptors, Thyroid Hormone/antagonists & inhibitors , Receptors, Thyroid Hormone/physiology , Repressor Proteins/chemistry , Repressor Proteins/metabolism , Stem Cells/cytology , Stem Cells/drug effects , p300-CBP Transcription FactorsABSTRACT
Drug addiction has great social and economical implications. In order to resolve this problem, the molecular and cellular basis for drug addiction must be elucidated. For the past three decades, our research has focused on elucidating the molecular mechanisms behind morphine tolerance and dependence. Although there are many working hypotheses, it is our premise that cellular modulation of the receptor signaling, either via transcriptional or post-translational control of the receptor, is the basis for morphine tolerance and dependence. Thus, in the current review, we will summarize our recent work on the transcriptional and post-translational control of the opioid receptor, with special emphasis on the mu-opioid receptor, which is demonstrated to mediate the in vivo functions of morphine.
Subject(s)
Narcotics/pharmacology , Opioid-Related Disorders/genetics , Opioid-Related Disorders/physiopathology , Receptors, Opioid/biosynthesis , Receptors, Opioid/metabolism , Receptors, Opioid/physiology , Transcription, Genetic/genetics , Animals , Drug Tolerance , Humans , Mice , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Receptors, Opioid/drug effects , Receptors, Opioid/genetics , Signal Transduction/drug effectsABSTRACT
Acute and chronic ethanol ingestion cause embryopathy similar to that of hyper- or hypovitaminosis A. Experimental data have suggested interaction between vitamin A and alcohol signaling pathways at the level of metabolic interference, which ultimately affects the concentration of retinoic acid (RA) in animals. The present study was set up to examine the possible effects of alcohol on cellular RA binding protein I (CRABP-I) expression during embryonic development by using transgenic mouse embryos and P19 embryonal carcinoma cells as experimental models. It was found that expression of the mouse CRABP-I gene was elevated in developing embryos at mid-gestation stages as a result of ethanol consumption by the mothers. Specific elevation of this gene was detected in the limb bud and the gut. In the P19 model, the CRABP-I gene was directly upregulated by ethanol, which was not blocked by a protein synthesis inhibitor. Furthermore, the regulation of the CRABP-I gene by ethanol was mediated by the 5' upstream regulatory region of the CRABP-I gene promoter. A potential interaction of vitamin A and ethanol at the level of CRABP-I gene expression is discussed.
Subject(s)
Ethanol/pharmacology , Receptors, Retinoic Acid/metabolism , Up-Regulation , Animals , Extremities/embryology , Gene Expression Regulation, Developmental , Genes, Reporter , Mice , Mice, Transgenic , Promoter Regions, Genetic , RNA/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Time Factors , Transfection , Tretinoin/pharmacology , Tumor Cells, Cultured , beta-Galactosidase/metabolismABSTRACT
A combination of in vivo and in vitro assays was employed to describe the ligand-independent interaction of the orphan nuclear receptor TR2 and histone deacetylase proteins. The repressive effect of TR2 on transcription of a luciferase reporter driven by a promoter containing a direct repeat-5 (DR5) derived from the human RARbeta gene was suppressed by the addition of the histone deacetylase inhibitor trichostatin A. Immunoprecipitation with FLAG-epitope (MDYKDDDDK)-tagged histone deacetylase proteins was used to demonstrate that TR2 and histone deacetylases 3 or 4 are present in the same immunoprecipitated complex. Deacetylase activity was demonstrated for these coimmunoprecipitates, further confirming the in vivo interaction of TR2 and histone deacetylases. Immunoprecipitation with anti-TR2 antibody was used to demonstrate interaction of TR2 with endogenously expressed histone deacetylases 3 and 4 in COS-1 cells. Dissection of TR2 domains showed that the DNA binding domain of the receptor was responsible for interaction with both histone deacetylases 3 and 4 in glutathione-S-transferase pull-down assays, while the ligand binding domain did not interact. The pull-down data were confirmed with far Western blots that also showed a direct interaction between labeled histone deacetylase proteins and TR2. It is suggested that repression mediated by unliganded TR2 is mediated, in part, by a direct interaction of this receptor with histone deacetylase proteins.
Subject(s)
Histone Deacetylases/metabolism , Receptors, Thyroid Hormone/physiology , Saccharomyces cerevisiae Proteins , Animals , Binding Sites , Blotting, Western , COS Cells , DNA/metabolism , DNA-Binding Proteins , Edetic Acid/pharmacology , Electrophoresis, Polyacrylamide Gel , Enzyme Inhibitors/pharmacology , Fungal Proteins/genetics , Glutathione Transferase/genetics , Herpes Simplex Virus Protein Vmw65/genetics , Histone Deacetylase Inhibitors , Humans , Hydroxamic Acids/pharmacology , Immunosorbent Techniques , Luciferases/genetics , Mice , Nuclear Receptor Subfamily 2, Group C, Member 1 , Promoter Regions, Genetic , Receptors, Retinoic Acid/genetics , Receptors, Thyroid Hormone/chemistry , Receptors, Thyroid Hormone/genetics , Recombinant Fusion Proteins , Transcription Factors/genetics , Transfection , Zinc/pharmacologyABSTRACT
Receptor-interacting protein 140 (RIP140) interacts with retinoic acid receptor and retinoid X receptor in a ligand-dependent manner and suppresses retinoic acid (RA) induction of its target genes. The receptor-interacting motif is mapped to a C-terminal peptide sequence (LTKTNPILYYMLQK) of RIP140. The functional role of this motif in mediating the suppressive effects of RIP140 on RA induction is demonstrated in mutation studies. RA induces coimmunoprecipitation of histone deacetylase 3 with retinoic acid receptor/retinoid X receptor in the presence of wild type RIP140, but not in the presence of the C-terminal motif-deleted RIP140. A decrease in histone acetylation on the promoter region that carries a RA response element is associated with the expression of wild type RIP140, but not with expression of the mutant RIP140, in a dose-dependent manner. These data provide a molecular explanation for RIP140 acting as a novel ligand-dependent, negative modulator of RA-regulated gene expression.
Subject(s)
Histone Deacetylases/metabolism , Nuclear Proteins/chemistry , Nuclear Proteins/metabolism , Receptors, Retinoic Acid/metabolism , Repressor Proteins/metabolism , Tretinoin/pharmacology , Acetylation , Adaptor Proteins, Signal Transducing , Amino Acid Sequence , Animals , Binding Sites , COS Cells , Chlorocebus aethiops , Chromatin/metabolism , Molecular Sequence Data , Mutagenesis , Nuclear Proteins/genetics , Nuclear Receptor Interacting Protein 1 , Promoter Regions, Genetic , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Retinoid X Receptors , Sequence Deletion , Transcription Factors/metabolism , TransfectionABSTRACT
The effect of retinoids on the expression of kappa opioid receptor (KOR) gene was examined in normal and transgenic animals. KOR-lacZ transgene expression was specifically elevated in KOR-positive areas of the developing CNS by depleting vitamin A from animal diets. The endogenous KOR mRNA species, including all three isoforms, were also upregulated by depleting vitamin A in developing animals. Change in the expression of isoforms a and b is similar in prenatal stages but differs during postnatal development. Interestingly, upregulation of isoform c is most significant postnatally. The regulation of KOR gene by vitamin A was substantiated in a mouse embryonal carcinoma P19 culture system in which retinoic acid (RA), the most potent ingredient of vitamin A, was able to suppress the expression of all the three KOR isoforms and KOR protein. The RA-mediated suppression was blocked by an RA receptor antagonist and a histone deacetylase (HDAC) inhibitor. By using a reporter transfection assay in P19 cells, the potential genetic element responsible for RA-mediated suppression of KOR gene expression was located to intron 1 of the mouse KOR gene, which could also be blocked by HDAC inhibitor. Furthermore, suppression of KOR gene expression by RA in P19 cells appeared to be an indirect event and required protein synthesis. A role of RA in KOR gene regulation during developmental stages was discussed.
Subject(s)
Gene Expression Regulation/drug effects , Receptors, Opioid, kappa/metabolism , Tretinoin/metabolism , Animals , Diet , Embryonal Carcinoma Stem Cells , Enzyme Inhibitors/pharmacology , Female , Genes, Reporter , Histone Deacetylase Inhibitors , Introns/drug effects , Male , Mice , Mice, Transgenic , Neoplastic Stem Cells/cytology , Neoplastic Stem Cells/metabolism , Organ Specificity , Protein Isoforms/genetics , Protein Isoforms/metabolism , RNA, Messenger/metabolism , Receptors, Opioid, kappa/genetics , Receptors, Retinoic Acid/antagonists & inhibitors , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Regulatory Sequences, Nucleic Acid/drug effects , Transfection , Transgenes , Tretinoin/pharmacology , Tumor Cells, Cultured , Vitamin A Deficiency/metabolismABSTRACT
The mouse kappa opioid receptor (KOR) gene is constitutively expressed in mouse embryonal carcinoma P19 stem cells and suppressed by retinoic acid (RA) in cells undergoing neuronal differentiation. A negative regulatory element is located within intron 1 of the KOR gene, which contains an Ikaros (Ik)-binding site (GGGAAgGGGAT). This sequence is an Ik-1 respondive, functionally negative element as demonstrated in the context of both natural KOR and heterologous promoters. The two underlined G residues of the second half-site are critical for Ik-1 binding and Ik-mediated repression of the KOR gene. RA induces Ik-1 expression within 1 day of treatment and suppresses KOR expression between 2 and 3 days. Overexpression of Ik-1 in P19 suppresses endogenous KOR gene expression, accompanied by increased binding of Ik-1 to the Ik-binding site and chromatin histone deacetylation on KOR promoters. It is proposed that in an RA-induced P19 differentiation model, RA elevates Ik-1 expression, which recruits histone deacetylase to intron 1 of the KOR gene and silences KOR gene promoters.
Subject(s)
Gene Silencing , Introns , Promoter Regions, Genetic , Receptors, Opioid, kappa/genetics , Transcription Factors/metabolism , Tretinoin/pharmacology , Acetylation , Animals , DNA-Binding Proteins/biosynthesis , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Gene Expression Regulation, Developmental , Histones/metabolism , Ikaros Transcription Factor , Mice , RNA, Messenger/biosynthesis , Receptors, Opioid, kappa/biosynthesis , Regulatory Sequences, Nucleic Acid , Transcription Factors/biosynthesis , Transcription Factors/genetics , Tumor Cells, CulturedABSTRACT
Cellular retinoic acid binding protein I (CRABP-I) plays a role in retinoic acid (RA) metabolism or transport. This report shows specific neuronal expression of CRABP-I in adult transgenic mouse brain using CRABP-I promotor-driven lac-Z and neuron- and astrocyte-markers. Double staining indicates that CRABP-I is expressed in neurons and large cells (>12 microm) but to much lesser degree the astrocytes. CRABP-I-lac-Z(+) neurons were distributed throughout the brain, but in a very discreet pattern in each brain region. CRABP-I expression in specific populations of brain neurons suggests that RA is extensively metabolized in mature brains, mostly in neurons. Additionally, the genetic basis of its specific expression in these brain areas is located in the 5' regulatory region of this gene.
ABSTRACT
Receptor-interacting protein 140 (RIP140) encodes a histone deacetylase (HDAC) inhibitor-sensitive repressive activity. Direct interaction of RIP140 with HDAC1 and HDAC3 occurs in vitro and in vivo as demonstrated in co-immunoprecipitation and glutathione S-transferase pull-down experiments. The HDAC-interacting domain of RIP140 is mapped to its N-terminal domain, between amino acids 78 and 303 based upon glutathione S-transferase pull-down experiments. In chromatin immunoprecipitation assays, it is demonstrated that histone deacetylation occurs at the chromatin region of the Gal4 binding sites as a result of Gal4 DNA binding domain-tethered RIP expression. The immunocomplexes of RIP140 from cells transfected with RIP140 and HDAC are able to deacetylate histone proteins in vitro. This study presents the first evidence for RIP140 as a negative coregulator for nuclear receptor actions by directly recruiting histone deacetylases and categorizes RIP140 as a novel negative coregulator that is able to directly interact with HDACs.
Subject(s)
Gene Silencing , Histone Deacetylases/metabolism , Nuclear Proteins/physiology , Adaptor Proteins, Signal Transducing , Animals , Binding Sites , COS Cells , Chromatin/metabolism , Histones/metabolism , Hydroxamic Acids/pharmacology , Nuclear Receptor Interacting Protein 1 , Receptors, TNF-Related Apoptosis-Inducing Ligand , Receptors, Tumor Necrosis Factor/analysis , Tretinoin/pharmacologyABSTRACT
The complete mouse orphan nuclear receptor TR2-11 gene structure and its 5'-untranscribed region were characterized. This gene contains 14 exons, with the first exon encoding only the 5'-untranslated sequence. The regulatory region of this gene was characterized by using reporter assays that define the minimal promoter activity in a sequence 212 nucleotides upstream from the translation initiation site. Furthermore, it was concluded that splicing of intron 1 is required for efficient promoter activity. Reporters driven by this promoter were induced by retinoic acid (RA) in COS-1 cells supplied with exogenous retinoic acid receptor-alpha (RAR(alpha)) and retinoid receptor X-beta (RXR(beta)). Binding of RAR(alpha)/RXR(beta) to the minimal promoter region was demonstrated in gel retardation assays. In P19 cells, both the endogenous TR2-11 gene and the reporters driven by this promoter were induced by RA in a protein synthesis-independent manner, and overexpression of TR2-11 protein resulted in cellular apoptosis in the absence of RA. The regulation of TR2-11 by RA and the implication of TR2 up-regulation in P19 cellular apoptosis are discussed.
Subject(s)
Apoptosis , Gene Expression Regulation , Promoter Regions, Genetic , Receptors, Thyroid Hormone/genetics , Tretinoin/pharmacology , Animals , Antineoplastic Agents/pharmacology , Cell Line , Exons , Mice , Nuclear Receptor Subfamily 2, Group C, Member 1 , Receptors, Thyroid Hormone/biosynthesis , Receptors, Thyroid Hormone/physiologyABSTRACT
The orphan nuclear receptor TR2 functions as a constitutive activator for the endogenous retinoic acid receptor beta2 (RAR(beta2)) gene expression in P19 embryonal carcinoma cells and for reporters driven by the RAR(beta2) promoter in COS-1 cells. The activation of RAR(beta2) by TR2 is mediated by the direct repeat-5 (DR5) element located in the RAR(beta2) promoter. Furthermore, cAMP exerts an enhancing effect on the activation of RAR(beta2) by TR2, which is mediated by the cAMP response element located in the 5'-flanking region of the DR5. The constitutive activation function-1 (AF-1) of TR2 is mapped to amino acid residues 10-30 in its N-terminal A segment. A direct molecular interaction occurs between CREMtau and TR2, detected by co-immunoprecipitation, which is mediated by the N-terminal AB segment of TR2. In gel mobility shift assays, TR2 competes with P19 nuclear factor binding to the RAR(beta2) promoter, and TR2 and CREMtau bind simultaneously to this DNA fragment. The role of TR2 in the early events of RA signaling process is discussed.
Subject(s)
DNA-Binding Proteins/pharmacology , Gene Expression Regulation , Nuclear Proteins/pharmacology , Promoter Regions, Genetic , Receptors, Retinoic Acid/genetics , Receptors, Steroid/metabolism , Receptors, Thyroid Hormone/metabolism , Animals , Base Sequence , Cell Line , Chromosome Mapping , Cyclic AMP/pharmacology , Electrophoresis, Polyacrylamide Gel , Molecular Sequence Data , Nuclear Receptor Subfamily 2, Group C, Member 1ABSTRACT
Three mRNA variants are generated from the mouse kappa-opioid receptor (KOR) gene. The expression patterns of these KOR mRNA variants in adult animal tissues and during developmental stages are examined. Furthermore, the biological significance of generating these variants is demonstrated with respect to two post-transcriptional mechanisms, i.e., mRNA stability and translation efficiency. Variants A and B are both transcribed from promoter 1 of the KOR gene and expressed from early developmental stages through adult life. Although their sequences differ only at a 30-nucleotide insertion for variant B, these two variants are distinct with regard to their expression patterns, mRNA stability, and translation efficiency. Variant A is expressed ubiquitously in all the tissues examined and has a longer t(1/2) (12 h), whereas variant B is more specific to the central nervous system both pre- and postnatally and has a t(1/2) of approximately 8 h. Variant C is transcribed from promoter 2 of the KOR gene and is most specifically expressed, being detected only in the brain stem, spinal cord, and thalamic/hypothalamic areas of postnatal animals. With regard to protein translation, variants B and C are significantly more efficient than variant A. This study provides the evidence for multiple levels of KOR regulation. The biological implication of the generation of KOR mRNA variants is discussed.
Subject(s)
Gene Expression Regulation, Developmental , Receptors, Opioid, kappa/genetics , Animals , Base Sequence , Mice , Molecular Sequence Data , Protein Biosynthesis , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Receptors, Opioid, kappa/biosynthesis , Sequence Homology, Nucleic Acid , Transcription, Genetic , Tumor Cells, CulturedABSTRACT
We have mutated the type I cellular retinoic acid binding protein (CRABP-I), individually at the Arg131 (into Ala) and the Tyr133 (into Phe) residues which have been predicted to make direct contact with retinoic acid (RA) based upon previous structural studies. The RA-binding affinities of these mutants are examined and their biological effects on RA induction of reporter genes are determined. The R131A mutation drastically affects its ligand-binding property, but the Y133F mutation has little effect. By using an RA-inducible reporter, it is found that the wild type CRABP-I exerts biphasic effects on RA induction of the reporter. The early (at 12 h) effect is to enhance RA induction, whereas the delayed (at 24 h) effect is to suppress RA induction. In consistence with their RA binding property, the R131A mutant loses both its early and delayed biological activities, whereas the Y133F mutant remains as effective as the wild type. It is concluded that CRABP-I over-expression exerts biphasic effects on RA-mediated gene expression, and that Arg131, but not Tyr133, is essential for a high RA-binding affinity of this protein as well as its biological activity.
Subject(s)
Point Mutation , Receptors, Retinoic Acid/genetics , Receptors, Retinoic Acid/metabolism , Alitretinoin , Animals , Base Sequence , Binding Sites/genetics , COS Cells , DNA Primers/genetics , Escherichia coli/genetics , Gene Expression , Genes, Reporter/drug effects , Humans , Luciferases/genetics , Mutagenesis, Site-Directed , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Tretinoin/metabolism , Tretinoin/pharmacologyABSTRACT
Receptor-interacting protein 140 (RIP140) contains multiple receptor interaction domains and interacts with retinoic acid receptors in a ligand-dependent manner. Nine LXXLL receptor-interacting motifs are organized into two clusters within this molecule, each differentially interacting with retinoic acid receptor (RAR) and retinoid X receptor (RXR). RAR interacts with the 5' cluster, whereas RXR interacts with both clusters. Additionally, a third ligand-dependent receptor-interacting domain is assigned to the very C terminus of this molecule, which contains no LXXLL motif. In mammalian cells, receptor heterodimerization is required for efficient interaction of RAR/RXR with RIP140. Furthermore, the heterodimeric, holoreceptors cooperatively interact with RIP140, which requires the activation function 2 domains of both receptors. By using different retinoic acid reporter systems, it is demonstrated that RIP140 strongly suppresses retinoic acid induction of reporter activities, but coactivator SRC-1 enhances it. Furthermore, an intrinsic repressive activity of RIP140 is demonstrated in a GAL4 fusion system. Unlike receptor corepressor, which interacts with antagonist-bound RAR/RXRs, RIP140 does not interact with antagonist-occupied RAR/RXR dimers. These data suggest that RIP140 represents a third coregulator category that is able to suppress the activation of certain agonist-bound hormone receptors.